文献速递淋巴瘤

克唑替尼联合化疗治疗儿童ALK阳性间变性大细胞淋巴瘤:儿童肿瘤协作组ANHL12P1试验结果

Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.
PubMed 文献 · J Clin Oncol · 2022-12-19

儿童肿瘤协作组ANHL12P1试验的克唑替尼组评估在初诊非局限性ALK阳性CD30阳性间变性大细胞淋巴瘤患儿的标准化疗中加入克唑替尼的疗效与毒性。2013至2019年共66例入组患儿接受克唑替尼联合化疗,2年无事件生存率为76.8%(95%CI 68.5至88.1),2年总生存率为95.2%(95%CI 85.7至98.4)。微小播散病灶阴性者无事件生存率85.6%,阳性者58.1%;66例中13例发生2级及以上血栓栓塞不良事件(19.7%)。

要点

  • 克唑替尼加入标准治疗可防止ALCL患儿治疗期间复发,但出现意外血栓栓塞事件。
  • 2年无事件生存率76.8%,2年总生存率95.2%。
  • 微小播散病灶阴性者无事件生存率85.6%,阳性者58.1%。

核心结论

  • ANHL12P1试验克唑替尼组表明,在标准治疗中加入克唑替尼可防止ALCL患儿治疗期间复发,微小播散病灶可预测无事件生存,且加入克唑替尼导致意外血栓栓塞事件。
  • 总生存率和无事件生存率与ALCL患儿报告的最高结局一致。

研究设计与样本

  • 儿童肿瘤协作组ANHL12P1试验(ClinicalTrials.gov标识NCT01979536)的克唑替尼组,评估在初诊非局限性ALK阳性CD30阳性间变性大细胞淋巴瘤患儿的标准化疗中加入克唑替尼的疗效和毒性。
  • 2013年至2019年共66例入组患儿接受克唑替尼联合化疗;患者接受5天前期治疗,随后每21天一个周期共6个化疗周期,每个21天周期内克唑替尼每日给药两次。
  • 研究因评估毒性暂时关闭两个时段(共12个月),期间停用克唑替尼;诊断时检测外周血NPM-ALK融合转录本以评估微小播散病灶。

主要发现

  • 2年无事件生存率为76.8%(95%CI 68.5至88.1),2年总生存率为95.2%(95%CI 85.7至98.4)。
  • 15例患者复发、1例患者死亡;中位复发时间为自诊断起7.4个月,复发均发生在化疗完成后。
  • 66例患者共完成384个化疗周期;66例中13例发生2级及以上血栓栓塞不良事件(19.7%;95%CI 11.1至31.3)。
  • 在接受强制预防性抗凝治疗的25例患者中,发生2例血栓栓塞事件(8.0%;95%CI 0.01至26)。
  • 微小播散病灶阴性者结局更优,无事件生存率为85.6%(95%CI 68.6至93.8);微小播散病灶阳性与较低的无事件生存率相关,为58.1%(95%CI 33.4至76.4)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Arm crizotinib (CZ) of the Children's Oncology Group trial ANHL12P1 (ClinicalTrials.gov identifier: NCT01979536) examined the efficacy and toxicity of adding CZ to standard chemotherapy for children with newly diagnosed, nonlocalized ALK+ CD30+ anaplastic large-cell lymphoma (ALCL). PATIENTS AND METHODS: Between 2013 and 2019, 66 enrolled children received CZ with chemotherapy. Patients received a 5-day prophase followed by six chemotherapy cycles at 21-day intervals with CZ administered twice daily during each 21-day cycle. The study was temporarily closed for two periods (total 12 months) to evaluate toxicity, during which CZ was discontinued. Measurements of NPM-ALK fusion transcripts in peripheral blood were performed at diagnosis for minimal disseminated disease (MDD). RESULTS: The 2-year event-free survival (EFS) is 76.8% (95% CI, 68.5 to 88.1) and the 2-year overall survival is 95.2% (95% CI, 85.7 to 98.4). Fifteen patients relapsed and one patient died; median time to relapse was 7.4 months from diagnosis, with relapses occurring after chemotherapy was complete. The 66 patients completed 384 cycles of chemotherapy. Thirteen of the 66 patients experienced a grade 2+ thromboembolic adverse event (19.7%; 95% CI, 11.1 to 31.3). In the 25 patients who received mandated prophylactic anticoagulation, there were two thromboembolic events (8.0%; 95% CI, 0.01 to 26). Patients with negative MDD had a superior outcome, with an EFS of 85.6% (95% CI, 68.6 to 93.8); positive MDD was associated with a lower EFS of 58.1% (95% CI, 33.4 to 76.4). CONCLUSION: Arm CZ of ANHL12P1 demonstrated that the addition of CZ to standard treatment prevented relapses during therapy for children with ALCL, MDD predicted EFS, and the addition of CZ resulted in unexpected thromboembolic events. Overall survival and EFS rates are consistent with the highest reported outcomes for children with ALCL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lowe EJ, Reilly AF, Lim MS, et al. Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1. J Clin Oncol. 2022. PMID: 36534942. doi:10.1200/JCO.22.00272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。